Bayer launches new reversible contraception method

Bayer has begun rolling out its intrauterine system Kyleena, a long-acting reversible contraception method, across the UK.

Phase III clinical trials of the intrauterine system concluded that the system has a 99 percent effectiveness rate, with low incidences of issues such as uterine perforation, ectopic pregnancy and pelvic inflammatory disease.

Regulators subsequently gave their approval to Kyleena, clearing the way for Bayer to put the system on the market.

Lars Bruening, chief executive of Bayer UK and Ireland, noted that 48 percent of women have missed a pill in the last three months, which can increase their chances of unplanned pregnancy.

"Kyleena provides women with an additional, reliable and reversible contraceptive option and highlights Bayer’s ongoing commitment to empower women with a broad range of birth control options at different stages of their lives," he commented.

The system works by continuously releasing a low dose of a progestogen called levonorgestrel, which thickens the cervical mucus and thins the endometrium, thereby inhibiting sperm function and movement.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.